These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11982725)

  • 21. New therapies on the horizon for hepatitis C: are we close?
    De Francesco R; Rice CM
    Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents].
    Watashi K; Shimotohno K
    Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Zhao Q; Xia N
    Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
    [No Abstract]   [Full Text] [Related]  

  • 27. S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells.
    Lozano-Sepulveda SA; Bautista-Osorio E; Merino-Mascorro JA; Varela-Rey M; Muñoz-Espinosa LE; Cordero-Perez P; Martinez-Chantar ML; Rivas-Estilla AM
    World J Gastroenterol; 2016 Apr; 22(14):3746-57. PubMed ID: 27076759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
    Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular virology of hepatitis C].
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.
    Mandour M; Vliegen I; Paeshuyse J; Neyts J
    Antiviral Res; 2018 Jan; 149():150-153. PubMed ID: 29154807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular mechanisms of the hepatitis C virus, potential therapeutic targets].
    Rivas-Estilla AM; Panduro A
    Rev Invest Clin; 2003; 55(1):51-64. PubMed ID: 12708164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A zebrafish model for subgenomic hepatitis C virus replication.
    Ding CB; Zhao Y; Zhang JP; Peng ZG; Song DQ; Jiang JD
    Int J Mol Med; 2015 Mar; 35(3):791-7. PubMed ID: 25572289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A primer on the molecular virology of hepatitis C.
    Moradpour D; Blum HE
    Liver Int; 2004 Dec; 24(6):519-25. PubMed ID: 15566499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approaches to the development of novel inhibitors of hepatitis C virus replication.
    Clarke BE
    J Viral Hepat; 1995; 2(1):1-8. PubMed ID: 7493290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
    Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
    Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
    Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
    Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
    Escuret V; Martin A; Durantel D; Parent R; Hantz O; Trépo C; Menguy T; Bottius E; Dardy J; Maral J; Escary JL; Zoulim F
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3984-91. PubMed ID: 17030563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental models for hepatitis C viral infection.
    Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
    Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.